ROIVANT SCIENCES LTD. Operating Lease, Weighted Average Discount Rate, Percent
ROIVANT SCIENCES LTD. (ROIV) had Operating Lease, Weighted Average Discount Rate, Percent of 7.40% as of 2026-03-31, per its 10-K filed 2026-05-20.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-05-20
- 2026-03-31: Operating Lease, Weighted Average Discount Rate, Percent 7.40%.
- 2025-03-31: Operating Lease, Weighted Average Discount Rate, Percent 7.40%.
- 2024-03-31: Operating Lease, Weighted Average Discount Rate, Percent 7.10%; Operating Lease, Weighted Average Discount Rate, Percent as first filed 7.40%.
- 2023-03-31: Operating Lease, Weighted Average Discount Rate, Percent 7.70%; Operating Lease, Weighted Average Discount Rate, Percent as first filed 7.90%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent | Operating Lease, Weighted Average Discount Rate, Percent as first filed |
|---|---|---|
| 2026-03-31 | 7.40% 10-K · filed 2026-05-20 | |
| 2025-03-31 | 7.40% 10-K · filed 2026-05-20 | |
| 2024-03-31 | 7.10% 10-K · filed 2026-05-20 | 7.40% 10-K · filed 2024-05-30 |
| 2023-03-31 | 7.70% 10-K · filed 2025-05-29 | 7.90% 10-K · filed 2023-06-28 |
| 2022-03-31 | 7.00% 10-K · filed 2023-06-28 | |
| 2021-03-31 | 7.10% 10-K · filed 2022-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |